OncoMatch/Clinical Trials/NCT06169072
Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients
Is NCT06169072 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Superparamagnetic Iron Oxide and Technetium99 for breast cancer.
Treatment: Superparamagnetic Iron Oxide · Technetium99 — The overall aim is to demonstrate that the use of superparamagnetic iron oxide nanoparticles (SPIO) as a tracer in an ultra-low dose (0.1 ml) is non-inferior for sentinel lymph node (SLN) detection in patients with breast cancer compared to the dual technique using Tc99m +/- blue dye, and to evaluate MRI breast artefacts and skin staining over time.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify